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Abstract
Disease overview: Cutaneous T-cell lymphomas are a heterogenous group of T-cell lymphoproli-
ferative disorders involving the skin, the majority of which may be classified as Mycosis Fungoides
(MF) or Sezary Syndrome (SS).
Diagnosis: The diagnosis of MF or SS requires the integration of clinical and histopathologic data.
Risk-adapted therapy: TNMB (tumor, node, metastasis, blood) staging remains the most important
prognostic factor in MF/SS and forms the basis for a “risk-adapted,” multi-disciplinary approach to
treatment. For patients with disease limited to the skin, expectant management or skin-directed
therapies is preferred, as both disease-specific and overall survival for these patients is favorable.
In contrast, patients with advanced-stage disease with significant nodal, visceral or blood involve-
ment are generally approached with biologic-response modifiers or histone deacetylase inhibitors
prior to escalating therapy to include systemic, single-agent chemotherapy. In highly-selected
patients, allogeneic stem-cell transplantation may be considered, as this may be curative in some
patients.
1 | DISEASE OVERVIEW
Primary cutaneous lymphomas are a heterogenous group of extranodal
non-Hodgkin lymphomas which, by definition, are largely confined to
the skin at diagnosis. The European Organization for Research and
Treatment of Cancer (EORTC) and World Health Organization (WHO)
published a consensus classification for cutaneous lymphomas in
2005.1 In contrast to nodal non-Hodgkin lymphoma, most of which are
B-cell derived, approximately 75% of primary cutaneous lymphomas
are T-cell derived, two-thirds of which may be classified as Mycosis
fungoides (MF) or Sezary Syndrome (SS).1–3 The incidence of cutane-
ous T-cell lymphomas (CTCL) has been increasing and is currently 6.4
per million persons, based on Surveillance, Epidemiology, and End
Results (SEER) registry data, with the highest incidence rates being
reported among males and African-Americans.2 While CTCL may occur
in children and young adults, this is very uncommon and often associ-
ated with histopathologic variants of MF.4–6 The incidence of CTCL
increases significantly with age, with a median age at diagnosis in the
mid-50’s and a four-fold increase in incidence appreciated in patients
over 70.2,6
Epidemiological studies have failed to consistently identify envi-
ronmental or virally associated risk factors for most CTCL subtypes,
with the notable exception of HTLV-1 infection in adult T-cell leuke-
mia/lymphoma.7 Recent studies, however, have suggested that medica-
tions may induce an antigen-driven T-cell lymphoproliferation or
dyscrasia.8,9 A recent case series examined a subset of hypertensive
MF patients using hydrochlorothiazide. When compared to hyperten-
sive MF patients not using hydrochlorothiazide, these patients were
more likely to have stage I disease, and were less likely to have a clonal
TCR gene rearrangement.9 More importantly, in a subset of these
patients, a complete or partial response was observed upon discontinu-
ation of hydrochlorothiazide. In three patients, CTCL recurred upon
reinitiating hydrochlorothiazide, and subsequently receded with its dis-
continuation. While these findings could be interpreted as a drug reac-
tion, more specifically a drug-induced pseudolymphoma, the authors of
this single center study speculate that hydrochlorothiazide may be
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associated with antigen-driven T-cell lymphoproliferation and could
serve as a trigger for MF. Consequently, a therapeutic trial off hydro-
chlorothiazide may be warranted in selected patients. Moreover, as a
variety of other medications may initiate a reaction mimicking MF, a
careful medication history should be performed in these patients with
a trial off any suspected offending drug. Individual genetic features
have also been implicated in the development of CTCL. Rare reports of
familial MF and the detection of specific HLA class II alleles in associa-
tion with both sporadic and familial MF suggest that host genetic fac-
tors may contribute to MF development.10–12 While the role of
environmental and host genetic factors in CTCL pathogenesis remains
unclear, significant insights into disease ontogeny, molecular pathoge-
nesis and disease-associated immune dysregulation have been
realized.13–16 Recently performed next-generation sequencing studies
have demonstrated a high frequency of C>T transitions, in contrast to
the T>G transversions observed in B-cell lymphproliferative disorders,
within NpCpC trinucleotides, a signature associated with ultraviolet B
(UVB) exposure in melanoma (reviewed in Ref. [17]).
1.1 | Cell of origin
Naïve T cells, upon encountering antigen in skin-draining lymph nodes,
inducibly express the E-selectin ligand cutaneous lymphocyte antigen
(CLA) and chemokine receptors (e.g., CCR4, CCR8, CCR10) that are
required for their subsequent trafficking to the skin.18–20 Clonal expan-
sion of activated T cells is followed by their differentiation into multiple
subsets of effector and memory cells. Central memory cells (TCM) retain
the ability to access the peripheral blood and lymph nodes. Effector
memory cells (TEM), in contrast, migrate into extranodal sites, including
the skin, where a subset will remain, as tissue-resident memory cells
(TRM). The majority of T cells in the skin are TRM,
18,21 express a high-
affinity antigen receptor,22 and have a distinct gene-expression pro-
file.23 Clonal T cells in MF are commonly TRM derived, thus explaining
their tendency to remain confined to the skin.24 Immunophenotyping
studies demonstrate that malignant T cells in patients with leukemic
CTCL variants (Sezary Syndrome and MF with secondary leukemic
involvement) express CCR7 and L-selectin, resembling TCM.
25 This fun-
damental difference in the putative cell of origin between SS (TCM
derived) and MF (TRM derived) is consistent with their distinct clinical
behavior, as TCM may be found in both the peripheral blood, lymph
node and skin and are long-lived cells resistant to apoptosis, while skin-
resident TRM cells fail to circulate in peripheral blood, remaining fixed
within the skin.25 In addition, a population of recirculating CCR71L-
selectin- migratory memory T cells (TMM) has been described in the
skin.21 Therefore, a subset of MF patients with secondary leukemic
involvement, poorly demarcated patches/plaques, more significant der-
mal involvement, and dermatopathic lymphadenopathy may harbor a
TMM-derived clone.
21 The contention that MF subtypes and SS origi-
nate from different T-cell subsets is consistent with comparative
genomic hybridization (CGH) and gene-expression profiling data dem-
onstrating that these CTCL subtypes are genetically distinct.26,27
Regulatory T cells (Treg) expressing the transcription factor FoxP3
are important in the maintenance of self-tolerance and form a minor
subset of skin-resident T cells. Heid et al. demonstrated that the malig-
nant T cells in a subset of Sezary patients may be derived from Treg
cells, as the malignant clone in these patients not only expressed
FoxP3 and suppressed conventional T cells, but possessed a demethy-
lated FoxP3 promoter.28 Uncertainties remain as to whether or not a
subset of Sezary patients harbor a clone that is derived from bona fide
skin resident Treg cells, or whether these cells aberrantly acquire a
Treg phenotype during disease evolution.29 For example, immature
dendritic cells, which are prevalent in CTCL,30 may upregulate FoxP3
expression in malignant T cells.31 Therefore, a subset of SS patients
appears to harbor a Treg-derived (or “Treg-like”) clone, although the
prognostic and therapeutic implications of this observation remain to
be defined.
In contrast to regulatory T cells, which represent a minority of
skin-resident T cells, the majority of T cells in the skin produce cyto-
kines characteristic of distinct effector T-cell subsets, including Th1,
Th2, and Th17 cells. This effector T-cell heterogeneity raises the possi-
bility that future studies may subclassify CTCL based on these T-cell
subsets.32,33 Of note, MF/SS is associated with the expression of Th2-
associated genes (e.g., GATA-3) and the production of Th2-associated
cytokines (e.g., IL-4, IL-5, IL-13), raising the possibility that a significant
subset of patients may harbor Th2-derived clones.34–38 Alternatively,
recurrent mutations activating specific signaling pathways (e.g., NFAT,
NFjB, JAK/STAT) may promote the acquisition of a particular pheno-
type independent of the cell of origin.39 T-cell differentiation is associ-
ated with considerable plasticity. Therefore, the phenotype of
malignant T cells may be both heterogeneous and highly dependent
upon cues within the microenvironment.31,40,41 As the genetic land-
scape and the putative cell of origin are further defined in subsets of
CTCL, including MF/SS, one may anticipate that this data may have a
significant impact on the classification, risk-stratification and treatment
of these diseases.17
1.2 | Immunopathogenesis
The establishment of long-term CTCL cell lines is challenging, as these
cells frequently undergo spontaneous cell death during in vitro cul-
ture42,43 (and personal observation). Therefore, the resistance to apo-
ptosis observed in vivo is unlikely due to an intrinsic resistance to
apoptosis alone. Rather, extrinsic factors present within the tumor
microenvironment likely contribute to the growth and survival of malig-
nant T cells, a contention supported by the observation that cytokine
supplementation or the provision of T-cell costimulatory signals sup-
ports the growth of malignant T cells in vitro.42,44,45 Both gene-
expression profiling and immunohistochemistry-based studies have
recently highlighted the important contribution of nonmalignant cells,
including monocyte-derived lymphoma-associated macrophages, in the
pathogenesis of both Hodgkin and non-Hodgkin lymphomas.46–48 Simi-
larly, malignant T cells in the skin are frequently associated with dendri-
tic cells and immunohistochemistry-based studies have clearly
demonstrated an abundance of both lymphoma-associated macro-
phages and dendritic cells, many of which may be actively recruited
into the tumor microenvironment by tumor-derived chemokines.30,49
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These monocyte-derived cells promote tumorigenesis both directly, by
the production of factors which promote tumor cell growth and sur-
vival, and indirectly, by supporting tumor angiogenesis and suppressing
host anti-tumor immunity.50 For example, monocyte-derived dendritic
cells supported the long-term survival of malignant T cells during in
vitro culture.43 More recently, peripheral blood monocytes (and their
progeny) were shown to support the growth of malignant T cells in
vitro, confer resistant to chemotherapy, and promote tumor engraft-
ment in immunodeficient mice.30 Lymphoma-derived IL-10, which is
upregulated in patients with advanced-stage, refractory disease,51
impairs the maturation of lymphoma-associated dendritic cells, render-
ing them immunologically incompetent, thus promoting escape from
host anti-tumor immune surveillance. In addition, lymphoma-associated
dendritic cells were observed to express the T-cell co-inhibitory ligand
B7-H1 (PD-L1, CD274), which directly inhibits the proliferation of
tumor-specific T cells, and indirectly impairs anti-tumor immunity by
promoting the induction of suppressive regulatory T cells.52 Therefore,
lymphoma-associated macrophages and dendritic cells appear to play
an important role in cutaneous T-cell lymphomagenesis while contrib-
uting to the evasion and suppression of host anti-tumor immunity.
In addition to the tumor microenvironment’s role, widespread
impairment of cellular immunity—the tumor “macroenvironment”—has
long been appreciated in CTCL and contributes to the significant mor-
bidity and mortality associated with infectious complications observed
in CTCL. Approximately 50% of patients with CTCL, particularly those
with advanced-stage disease, will ultimately succumb to infectious
complications.53–55 Both quantitative and qualitative defects in natural
killer (NK) cell,56,57 dendritic cell58 and T cell-mediated59–61 immunity
are observed in CTCL. In addition, CTCL is associated with a significant
loss of the T-cell repertoire, analogous to that observed in HIV infec-
tion. T-cell receptor (TCR) diversity within multiple TCR beta-variable
(Vb) families was analyzed using complementarity-determining region 3
(CDR3) spectratyping and combined with a quantitative analysis of
TCR-Vb usage by flow cytometry.62 In patients with advanced-stage
disease, and half of patients with limited-stage disease, a dramatic loss
of TCR diversity was observed. Whether this observation may be
explained by tumor-mediated suppression of nonmalignant T cells,
diminished thymic output of naïve T cells and compensatory homeo-
static expansion of oligoclonal peripheral T cells, or some other mecha-
nism, is unknown.51 As lymphopenia is an adverse prognostic factor in
many hematologic malignancies,63–68 and undoubtedly contributes to
the infectious complications observed in CTCL, improved understand-
ing of the causative mechanism(s) leading to this dramatic loss of T-cell
diversity may have significant therapeutic implications.
1.3 | Molecular pathogenesis
Recently performed genomic analyses have elucidated the complexity
of the genetic landscape in CTCL, including a significant number of
copy number variants that implicate well established tumor suppressor
genes, including p53, in disease pathogenesis (reviewed in Ref. [17]). In
addition to focal, and in many cases widespread, amplifications and
deletions, several pathways regulating cell growth and survival are
recurrently mutated. Among these, mutations involving components of
the chromatin remodeling SWI/SNF complex and various epigenetic
regulators are highly prevalent in CTCL (reviewed in Ref. [17]), as are
mutations targeting the CDKN2A-CDKN2B locus.17,69,70 In addition,
recurrent activating mutations in signaling intermediates required for
antigen-, costimulatory, and cytokine receptor signaling in conventional
T cells have been identified, thus implicating these “three signals” in
CTCL pathogenesis (reviewed in Refs. [71,72]). For example, The NF-
kB family of transcription factors (i.e., c-rel, p65/RelA, RelB, p50/p105,
p52/p100) plays an important role in normal lymphocyte development,
activation and differentiation via the regulation of target genes
involved in cell growth, survival and cytokine production. Multiple
mechanisms, well described in B-cell lymphomas, lead to constitutive
NF-kB activation, promoting lymphomagenesis.73 In a similar fashion,
NF-kB is constitutively activated in CTCL.74–76 Immunohistochemical
analysis of MF cases demonstrated nuclear localization of p65/RelA in
over 90% of the cases examined.74 Furthermore, pharmacologic NF-kB
inhibition in CTCL cell lines decreases NF-kB DNA binding activity,
thus promoting cell death.74–77 Recurrent activating mutations in the
TRAF2 regulatory domain of TNFRSF1B (TNFR2) lead to ligand-
independent activation of canonical NF-jB signaling and may confer
sensitivity to proteasomal inhibition.17 CARD11, a component of the
CBM complex required for T-cell receptor (TCR) signaling and NF-jB
activation, is mutated or subject to copy number gains.17 A recurrent
deletion involving the C-terminus of NFkB2 leads to impaired degrada-
tion, leading to its constitutive activation and potentiation of TCR
signaling.17
The signal transducers and activators of transcription (STATs) are a
family of six transcription factors which become phosphorylated by
one of four upstream receptor-associated Janus kinases (JAKs) follow-
ing cytokine stimulation. Nuclear localization and DNA-binding of
phosphorylated STAT3 has been convincingly demonstrated in
CTCL.78,79 Following nuclear translocation, STAT3 directly regulates a
number of target genes in CTCL, including regulators of apoptosis (e.g.,
Bcl-2/Bax), cytokines (e.g., IL-5, IL-13) and suppressors of cytokine sig-
naling (e.g., SOCS). In addition, STAT3 indirectly regulates gene expres-
sion by inducing the expression of DNA methyltransferase 1 (DNMT1),
which promotes the epigenetic silencing of tumor suppressor genes.80
Not surprisingly then, pharmacologic inhibition of STAT3 promotes
apoptosis in CTCL.78,81–83 Cytogenetic gains involving STAT5A and
STAT5B or their activation in response to cytokines present within the
tumor microenvironment suggests a pathogenic role for other
STATs,41,84–86 and is further supported by recurrent activating muta-
tions observed in JAK1, JAK3, STAT3, and STAT5B.17
2 | DIAGNOSIS
2.1 | Mycosis fungoides
The definitive diagnosis of MF, particularly patch/plaque stage disease,
is challenging, as many of its clinical and pathologic features are non-
specific. Many patients will have had symptoms attributed to eczema
or parapsoriasis for years prior to obtaining a definitive diagnosis. The
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median time from symptom onset to diagnosis in retrospective series is
3–4 years, but may exceed four decades.87–89 Given the importance of
clinicopathological correlation in the diagnosis of MF and the variable
association of specific histologic findings with the diagnosis, biopsy
reports are not infrequently “suggestive of” the diagnosis. This occa-
sional uncertainty implied in biopsy reports and apparent lack of a
more definitive histopathologic diagnosis may be a source of frustra-
tion for clinicians unfamiliar with the challenges associated with render-
ing a pathologic diagnosis of MF. While a definitive diagnosis of MF
may be made on the basis of clinical and histopathologic features alone,
determination of T-cell clonality and assessment for the aberrant loss
of T-cell antigen expression by immunohistochemical staining for CD2,
CD3, CD5, and CD7 are useful ancillary studies in the diagnosis of MF
(and SS). PCR-based methods are able to detect clonal rearrangements
of the T-cell receptor (TCR) in formalin-fixed, paraffin-embedded
biopsy specimens.90,91 PCR-based methods, while sensitive, should be
interpreted with caution, as clonal TCR gene rearrangements may be
detected in normal elderly individuals and in patients with benign der-
matoses or other disease states.92–96 However, detection of identical
clones from two different sites is quite specific for MF.97 The extent to
which MF/SS may be preceded by a premalignant state, analogous to
monoclonal B-cell lymphocytosis (MBL) or monoclonal gammopathy of
undetermined significance (MGUS), is debatable and poorly defined.98
The malignant lymphocytes in MF/SS are usually CD31CD41 and
CD8-, but frequently lose the expression of other pan-T-cell antigens.
Therefore, demonstration of a significant population of CD41 cells
lacking CD2, CD5, and/or CD7 expression is highly specific (specificity
>90%) for MF in most reported series.99,100 Clinically, patch/plaque
stage MF is frequently characterized by persistent and progressive
lesions that develop in a “bathing suit” distribution and vary in size,
shape and color. These lesions are frequently large (>5 cm), pruritic and
multifocal in “classical” MF. However, a broad range of MF variants
have been described with differences in tropism (e.g., follicular MF), dis-
tribution (e.g., palmoplantar MF), pigmentation (e.g., hypo- and hyper-
pigmented variants) and focality (e.g., unilesional MF), some of which
are formally recognized in the WHO-EORTC classification.1,101 Given
the need for uniform diagnostic criteria in MF, the International Society
for Cutaneous Lymphoma (ISCL) recently proposed a point-based diag-
nostic algorithm which integrates clinical, histopathologic and immuno-
phenotyping data with an assessment of T-cell clonality.102
2.2 | Sezary syndrome
Traditionally, SS is defined as a leukemic form of CTCL associated with
erythroderma. A series of studies in the early to mid-20th century,
beginning with Sezary’s initial landmark observation in 1938, identified
a population of large lymphocytes in the peripheral blood with grooved,
lobulated (that is, “cerebriform”) nuclei in patients with MF or
SS.103–108 As in other chronic lymphoproliferative disorders, the Sezary
cell count is preferably expressed in absolute terms, with 1000 cells/
ml classified as B2 disease in the current ISCL/EORTC TNMB staging
classification. The morphologic detection of Sezary cells in the periph-
eral blood is not specific for CTCL, as Sezary cells may be found in
peripheral blood from normal donors and in benign conditions.109–111
The histologic findings in the skin often resemble those observed in
MF, with less prominent epidermotropism, while lymph node involve-
ment is characterized by complete effacement of the nodal architec-
ture by infiltrating Sezary cells.112
In SS, clonal T cells are generally CD31CD41 and CD8- by multi-
color flow cytometry.113–116 As in MF, the aberrant loss of pan-T-cell
antigens, including CD2, CD3, CD4, CD5, CD7 and/or CD26 is fre-
quently observed.115,117–120 Of these, the aberrant loss of CD7 and/or
CD26 expression is most common, being observed in most
cases.116,117,121–125 The loss of CD7 (40%) and/or CD26 (80%) is
sensitive (>80%) and highly specific (100%) for SS.120 The aberrant
expression of the MHC class I-binding, killer immunoglobulin-like
receptor (KIR) CD158j (and less commonly CD158a or CD158b), nor-
mally expressed by natural killer cells, was described in the majority of
patients examined with SS.120,126,127 Molecular studies, including
detection of a clonal TCR gene rearrangement by PCR and the pres-
ence of a clonal cytogenetic abnormality, provide evidence of T-cell
clonality. An alternative approach to demonstrate T-cell clonality incor-
porates multi-color flow cytometry using a panel of antibodies specific
for various TCR beta-chain variable region family members (TCR-
Vb).128–130 This approach is successful in identifying a clonal popula-
tion of T cells if this population is significantly higher than the back-
ground frequency of polyclonal T cells harboring the same Vb
chain.128,129 Clark et al. observed that lymphocytes isolated from either
peripheral blood or skin lesions of CTCL patients contained a popula-
tion of cells with high forward and side scatter characteristics on flow
cytometric analysis.131 A similar population of so-called high-scatter T
cells (THS) was not observed in samples obtained from patients with
benign conditions. More importantly, these high-scatter T cells, upon
careful immunophenotyping and analysis of clonal TCR-Vb chain
expression, were convincingly shown to represent the malignant T cell
clone. While additional confirmatory studies are warranted, detection
of high-scatter T cells may be an easily performed method to detect a
clonal T-cell population in patients with limited-stage MF and to moni-
tor the response to therapy.
The currently proposed ISCL criteria for SS integrate clinical, histo-
logic, immunophenotyping and molecular studies. In patients with
erythroderma, criteria recommended for the diagnosis of SS by the
ISCL include the following: absolute sezary count 1000/ml, a CD4/
CD8 ratio 10 (due to the clonal expansion of CD41 cells), aberrant
expression of pan-T-cell antigens, demonstration of T-cell clonality by
Southern blot or PCR-based methods, or cytogenetic demonstration of
an abnormal clone.115 At a minimum, the WHO-EORTC recommends
the demonstration of T-cell clonality in combination with the above-
mentioned criteria for the diagnosis of SS.1 In addition to the ISCL cri-
teria, the most recent WHO classification requires erythroderma, gen-
eralized lymphadenopathy, and clonally related T-cells (Sezary cells) in
the skin, peripheral blood, and lymph nodes. On rare occasions, SS may
be preceded by a prior history of classic MF. The ISCL recommends
that such cases be designated as “SS preceded by MF.” Conversely,
patients with MF, but without erythroderma, may meet hematologic
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criteria for SS. In these cases, the designation “MF with leukemic
involvement” is recommended.
2.3 | Non-MF/SS subtypes of CTCL
An important goal during a patient’s initial diagnostic evaluation is to
distinguish non-MF/SS CTCL subtypes from MF/SS, as the natural his-
tory, prognosis, and treatment approach for each of the non-MF/SS
lymphomas is highly variable. A detailed description of these CTCL sub-
types is beyond the scope of this update, but the salient features of
each have been previously summarized.1,132
3 | RISK-STRATIFICATION
3.1 | Staging
In contrast to many other lymphoproliferative disorders in which cyto-
genetic and laboratory findings play a prominent role in risk stratifica-
tion, TNMB (tumor, node, metastasis, blood) staging remains an
important prognostic factor in MF/SS and forms the basis for a “risk-
adapted” approach to treatment. In 2007, the ISCL and EORTC revised
the TNMB staging of MF/SS.133 Patients with only patches and pla-
ques have stage I disease, but may be further divided into stage IA
(<10% body surface area involved or T1) or stage IB (>10% body sur-
face area involved or T2) based on the extent of skin involvement. For
practical purposes, the area of one hand (including both palm and dig-
its) represents approximately 1% of body surface area. Current staging
and diagnostic recommendations do not require a biopsy of clinically
normal lymph nodes; however, an excisional biopsy of any abnormal
lymph nodes (1.5 cm in diameter or firm/fixed) is recommended, with
preference being given either to the largest lymph node draining an
area of skin involvement or to the node with the greatest standardized
uptake value (SUV) on FDG-PET imaging. In current practice, two path-
ologic staging systems are used to classify the extent of nodal involve-
ment. In the Dutch system, lymph nodes are pathologically graded
based on the presence of large cerebriform nuclei (>7.5 mm) and the
degree of architectural effacement.134 In contrast, the NCI-VA classifi-
cation uses the relative number of atypical lymphocytes (not size),
along with nodal architecture to determine the extent of nodal involve-
ment.135,136 Patients with patch/plaque stage disease (T1/T2) and
architectural preservation of any clinically abnormal lymph nodes are
classified as stage IIA. Collectively, patients with stage I-IIA disease
have “limited-stage” disease, as the overall survival in these patients is
measured in decades, with survival in patients with stage IA disease
resembling that of normal age-matched controls.6,87,88 At diagnosis,
the majority of MF patients will have limited-stage disease.6 In con-
trast, patients with tumor stage disease (T3), erythroderma (T4), nodal
involvement characterized by partial or complete architectural efface-
ment (N3), visceral metastases (M1), or significant leukemic involve-
ment (B2) have “advanced-stage” disease. Detection of a clonal TCR
gene rearrangement by PCR, which has been incorporated into the
revised ISCL/EORTC node(N) and blood(B) staging classification, is an
adverse prognostic factor.6,137–140 Unfortunately, median survivals
from approximately 1–5 years are observed in these patients with
more extensive disease.6 The revised ISCL/EORTC staging for MF/SS
is summarized in Table 1.
A retrospective study including 1398 MF patients, 71% with patch/
plaque stage disease, and 104 SS patients has validated the revised
ISCL/EORTC staging classification.6 On univariate and multivariate anal-
yses, the revised T, N, M, and B classification were significantly associ-
ated with overall and disease-specific survival. The median survival,
disease-specific survival and risk of disease progression, by clinical stage,
are summarized in Table 1. In addition to staging, male gender, increas-
ing age, an elevated LDH and the folliculotropic variant of MF were also
independently associated with poorer overall and disease-specific sur-
vival. In contrast to previous reports highlighting the aggressive clinical
course associated with large cell transformation,141–145 defined as the
presence of large, atypical lymphocytes comprising at least 25% of the
total lymphoid infiltrate, large cell transformation was not an independ-
ent predictor of overall or disease-specific survival, but was associated
with a higher risk (hazard ratio 3.32) of disease progression.6 Given the
importance of the TNMB classification in risk stratification and defining
TABLE 1 ISCL/EORTC staging
TNMB Classification 10-year6
Stage T N M B Median OS (years) OS (%) DSS (%) RDP (%)
IA 1 0 0 0,1 35.5 88 95 12
IB 2 0 0 0,1 21.5 70 77 38
IIA 1, 2 1 0 0,1 15.8 52 67 33
IIB 3 0–2 0 0,1 4.7 34 42 58
IIIA 4 0–2 0 0 4.7 37 45 62
IIIB 4 0–2 0 1 3.4 25 45 73
IVA1 1–4 0–2 0 2 3.8 18 20 83
IVA2 1–4 3 0 0–2 2.1 15 20 80
IVB 1–4 0–3 1 0–2 1.4 18 (5 year) 18 (5 year) 82 (5 year)
OS, overall survival; DSS, disease-specific survival; RDP, risk of disease progression.
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disease burden, the ISCL/EORTC recommends its use in defining the ini-
tial, maximum and current burden of disease, which will ultimately play
an important role in the selection of either skin-directed or systemic
therapies.133 In the future, it is anticipated that improved understanding
of the genetic landscape will further improve risk-stratification and lead
to a more personalized approach for treatment selection in CTCL.17
Recognizing that the staging system used for MF/SS is less helpful
for non-MF/SS cutaneous lymphomas, a new TNM classification was
also proposed for these CTCL variants.146 Due to the significant heter-
ogeneity of these lymphomas, this staging system does not provide
prognostic information, but is intended to provide a uniform descrip-
tion of the disease burden.
3.2 | Treatment of limited-stage MF
As the majority of CTCL patients present with patch/plaque stage MF
and have an excellent prognosis, the initial goal of therapy is to
improve symptoms and quality of life while avoiding treatment-related
toxicity. For many patients, this may involve either expectant manage-
ment (i.e., “watch and wait”) or skin-directed therapies. A randomized
trial comparing early combined modality therapy, including both radia-
tion and multiagent chemotherapy (cyclophosphamide, doxorubicin,
etoposide, and vincristine), with sequential topical therapies demon-
strated that combined-modality therapy, while associated with a supe-
rior complete response rate, did not translate into improvements in
disease-free or overall survival and was associated with significant tox-
icity.147 The limited efficacy associated with chemotherapy has been
highlighted in retrospective studies in which the median time to next
treatment following single or multiagent chemotherapy was 4
months.148,149 Therefore, patients with limited-stage disease who
require therapy are best approached with skin-directed therapies, usu-
ally under the direction of a dermatologist and/or radiation oncologist.
Excellent reviews and treatment guidelines are available.132,150–155
3.3 | Treatment of advanced-stage MF/SS
3.3.1 | Overview
Patients with advanced-stage MF/SS require a multidisciplinary
approach, as various combinations of skin-directed therapies, biologic-
response modifiers and ultimately the sequential use of systemic che-
motherapeutic agents are frequently employed in the management of
these patients. As for limited-stage disease, multiagent chemotherapy,
with only few exceptions, is generally not appropriate.147 A “risk-
adapted” stage-based approach is adopted, with biologic-response
modifiers (e.g., bexarotene and interferon-alpha) and histone deacety-
lase inhibitors (e.g., vorinostat) generally preferred prior to escalating
therapy to include systemic chemotherapy.156 Therapeutic decisions
are individualized and based on a patient’s age, performance status,
extent of disease burden, the rate of disease progression, and previous
therapies.150–155
3.3.2 | Bexarotene
The endogenous retinoids all-trans retinoic acid and 9-cis retinoic acid
(i.e., vitamin-A-derived compounds) regulate a diverse array of biologic
processes, ranging from embryonic development to cell growth, differ-
entiation and survival, upon binding two families of steroid hormone
receptors, the retinoic acid receptors (RAR) and retinoid X receptors
(RXR). Upon forming homo- or heterodimers, these receptors recruit
various nuclear co-repressor or co-activator proteins depending
whether or not they are bound by ligand. Multiple RAR retinoids have
been used in MF/SS, either topically or systemically (reviewed in
Refs. [157,158]), with response rates exceeding 50%. However, in
1999 the oral RXR-selective “rexinoid” bexarotene was FDA approved
for CTCL and was later approved as a topical gel formulation. Labora-
tory studies demonstrate that bexarotene promotes cell cycle arrest
and apoptosis in CTCL cell lines.159,160 In a multicenter phase II-III
study, 94 patients with advanced-stage CTCL who had been previously
treated with a median of five prior therapies, the vast majority of
whom had disease refractory to at least one prior systemic therapy,
received at least 300 mg/m2 of oral bexarotene daily.161 Among
patients treated at the 300 mg/m2 dose, an overall response rate of
45% was observed, only 2% of which were complete. While an
improved overall response rate was noted with the use of higher doses,
this difference was not statistically significant, and dose-limiting toxic-
ity was far more common (50% vs. 89%) in these patients. While a
dose-response relationship is likely, the 300 mg/m2 dose appears to
provide the optimal risk-benefit ratio. The most common toxicities
associated with therapy were hypertriglyceridemia (in 82%) and central
hypothyroidism (29%). Myelosuppression is infrequent and usually
uncomplicated. Pancreatitis secondary to hypertriglyceridemia may be
rarely observed, but is reversible upon discontinuation of treatment.
Therefore, a baseline lipid panel and TSH should be obtained prior to
the initiation of therapy. In one retrospective study, all patients treated
with bexarotene developed hyperlipidemia and hypothyroidism,
frequently within weeks of initiating treatment.162 Consequently,
use of lipid-lowering agents (e.g., fenofibrate) and low-dose levothyrox-
ine (e.g., 50 mg) prior to initiating bexarotene is generally
recommended.163–165 In clinical practice, bexarotene is frequently initi-
ated at a lower dose of 150 mg/m2 and subsequently titrated to full
doses after 4 weeks of therapy, depending upon patient tolerability.
Most responses occur within 2–3 months of treatment initiation, but
may be delayed. Therefore, in the absence of disease progression or
toxicity, treatment should be continued for up to 6 months. For
responding patients, treatment should be continued until disease pro-
gression and, depending upon the quality of the response, adjunctive
skin-directed therapies (e.g., PUVA, interferon) should be consid-
ered.166 Guidelines describing appropriate laboratory monitoring, sup-
portive care, and safe clinical prescribing of bexarotene have been
recently published.165 Future studies clarifying the optimal use of bex-
arotene, either in combination or sequentially with other agents, are
needed.
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3.3.3 | HDAC inhibitors
Histone deacetylases (HDACs) catalyze the removal of acetyl groups
from both histone and nonhistone proteins. As histone acetylation is
associated with an open chromatin configuration associated with active
gene transcription, HDACs contribute to histone deacetylation and the
epigenetic repression of gene transcription. As HDACs regulate a wide
variety of processes involved in carcinogenesis, multiple mechanisms
may explain the clinical activity of HDAC inhibitors,167,168 including
altered gene expression of cell-cycle and apoptotic regulatory
proteins,169–173 acetylation of nonhistone proteins regulating cell
growth and survival,174–177 angiogenesis,178,179 aggresome forma-
tion,180 and DNA repair.181 In addition, HDAC inhibitors may have
important effects on the tumor microenvironment via reactive oxygen
species,182,183 enhanced antigen presentation,184 and downregulation
of immunomodulatory cytokines, like IL-10.185
Vorinostat (suberoylanilide hydroxamic acid, SAHA) and romidep-
sin (depsipeptide) inhibit class I and II HDACs (i.e., pan-HDAC inhibi-
tors), the former being widely expressed in various lymphoma
subtypes.186 Early phase I studies of both vorinostat and romidepsin
established their safety and potential efficacy in lymphoproliferative
disorders, including CTCL,187 thus paving the way for larger phase II
studies. An earlier phase II study established 400 mg of oral vorinostat
once daily as the optimal dose that was investigated further in 74 pre-
viously treated patients with CTCL, most of whom (>80%) had
advanced-stage disease.188,189 The overall response rate was approxi-
mately 30% for patients with advanced-stage disease and was associ-
ated with a median duration of response estimated to exceed 185
days. Most responses were rapid (i.e., <2 months) and were also noted
in patients with tumor-stage disease and Sezary syndrome.190 Patients
who failed to achieve an objective response appeared to derive some
clinical benefit, including stable disease, decreased lymphadenopathy
and pruritis relief, with treatment. The most common nonhematologic
adverse events, observed in almost 50% of patients, were gastrointesti-
nal toxicities (nausea, vomiting, diarrhea). Hematologic toxicities,
including anemia or thrombocytopenia, were observed in up to 20% of
patients. Among responding patients, long-term therapy with vorino-
stat appears to be well tolerated.191 Prolongation of the QT interval
was rarely observed, but monitoring and appropriate electrolyte
replacement is recommended for those patients at risk for QT
prolongation.192
Romidepsin, administered as a 4-hour intravenous infusion
(14 mg/m2) days 1, 8 and 15 every 4 weeks, was evaluated in two
phase II studies, the largest of which included 96 patients, most with
advanced-stage disease.193,194 The overall response rate was 38% for
patients with advanced-stage disease, with a median duration of
response that exceeded one year. A toxicity profile similar to that
described for vorinostat was observed. Intensive cardiac monitoring in
a subset of these patients failed to demonstrate any clinically signifi-
cant cardiotoxicity.195
Additional HDAC inhibitors, including potent pan-HDAC inhibitors,
appear to have activity in CTCL.173,196,197 Further studies are needed
to fully define the mechanisms of resistance to HDAC inhibition in
CTCL,173,198–202 enabling the development of rational therapeutic
combinations incorporating HDAC inhibitors in CTCL.203,204
3.3.4 | Interferon-alpha
Interferon-alpha (i.e., interferon-alpha 2b), a type I interferon with
immunomodulatory properties, has pleiotropic effects in CTCL and is
associated with an overall response rate of 50–70% and a complete
response rate of 20–30%, particularly in patients with limited-stage
disease.205–208 While often considered as second-line therapy for
limited-stage CTCL, interferon-alpha, frequently at doses ranging from
3–10 million units daily to three times weekly, is a treatment to be con-
sidered in the first-line setting in patients with advanced-stage disease.
Responses, which may be achieved within a few months, are observed
in patients with tumor-stage MF and SS, and are occasionally dura-
ble.148,209 Furthermore, interferon-alpha may be successfully combined
with a number of other therapeutic modalities frequently utilized in the
management of these patients, including PUVA, bexarotene, chemo-
therapy and ECP.210–223 For example, in a cohort of 51, mostly
advanced-stage patients treated with single-agent, low-dose,
interferon-alpha, responses were observed in 34 (67%), including 21
(41%) with a complete response and 9 with a long-term remission.208
Similarly, in a cohort of 47 patients with stage III/IV disease, 89% of
whom had peripheral blood involvement, a response rate exceeding
80% was observed in those treated with a combination of ECP and
interferon-alpha.223 Interferon-alpha is associated with myelosuppres-
sion, transaminitis and dose-limiting flu-like side effects, particularly at
higher doses.
3.3.5 | Extracorporeal photophoresis
During extracorporeal photophoresis (ECP) pooled leukapheresis and
plasmapheresis products are exposed to 8-methoxypsoralen (8-MOP)
prior to extracorporeal circulation through a 1 mm thick disposable cas-
sette exposed to UVA radiation. The irradiated leukocytes, represent-
ing approximately 5% of peripheral blood leukocytes, are subsequently
reinfused. Psoralen covalently binds and crosslinks DNA following UVA
exposure, leading to the induction of apoptosis in the majority of
treated lymphocytes by multiple mechanisms involving bcl-2 family
members, disruption of the mitochondrial membrane potential and
extrinsic cell death pathways.224–226 In contrast, ECP leads to mono-
cyte activation, including significant changes in gene expression,227 and
dendritic cell differentiation, which is thought to culminate in enhanced
antigen presentation and the initiation of a host immune response.228
In hopes of prolonging the exposure time between monocyte-derived
dendritic cells and malignant lymphocytes undergoing apoptosis, inves-
tigators have developed a modified ECP protocol (i.e., “transimmuniza-
tion”) whereby blood products are incubated overnight following UVA
irradiation and prior to patient infusion.229 This novel adaptation is
investigational and has not been widely employed given concerns
about infectious risks and lack of a proven increase in efficacy.
Following the landmark study by Edelson and colleagues describ-
ing responses in 27 out of 37 patients with erythrodermic CTCL
treated with ECP, ECP was approved by the Food and Drug Adminis-
tration of the USA for the treatment of CTCL and is now considered
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the treatment of choice in the first-line management of patients with
Sezary syndrome in many centers.230 While responses vary between
case series, overall response rates hover around 60%, with a complete
response rate of approximately 20%.231–234 As current treatment pro-
tocols no longer require the oral administration of 8-MOP, eliminating
nausea, ECP is safe and generally very well tolerated. While alternative
schedules have been investigated, ECP is generally performed for 2
consecutive days every 2–4 weeks. While the precise mechanism of
action is incompletely understood, evidence suggests that ECP has
immunomodulatory effects which may augment host anti-tumor immu-
nity. It is not surprising then that the median time to response follow-
ing the initiation of ECP is approximately 6 months. Median survival
exceeding 8 years has been observed in ECP treated patients and
among complete responders, many experience durable responses
which may permit, for some, weaning from CTCL-directed
therapies.231,235–237 While patient- or disease-specific factors which
may predict a response to therapy are imperfect, patients for whom
treatment is initiated promptly after diagnosis who have circulating
Sezary cells, but without significant nodal or visceral disease, may be
more likely to respond. In addition, patients without profound immune
deficiencies, reflected by normal or near-normal cytotoxic T-cell and
CD4/CD8 values and the absence of prior exposure to systemic chem-
otherapy, may be more likely to respond to therapy.231,233,236 While
effective as monotherapy, ECP has also been combined with other
therapeutic strategies, including interferon, bexarotene and
TSEBT.213,223,235,238–240
3.3.6 | Monoclonal antibodies and immunotoxins
In contrast to many B-cell lymphoproliferative disorders, where the
incorporation of CD20-targeting monoclonal antibodies has become
the standard of care, additional studies are needed to identify the opti-
mal approach targeting T-cell specific antigens in advanced-stage MF/
SS. Alemtuzumab is a humanized IgG1 monoclonal antibody directed
against CD52, an antigen widely expressed by B-cells, T-cells and
monocytes.241 In a phase II study in 22 patients with advanced-stage
MF/SS, overall and complete response rates of 55% and 32%, respec-
tively, were observed, with a median time to treatment failure of 1
year.242 Given the significant risk of infectious complications, low-dose
subcutaneous alemtuzumab was investigated in 14 patients with SS,
most of whom had relapsed/refractory disease.243 Most patients in
this study received 3 mg of subcutaneous alemtuzumab on day 1 fol-
lowed by a 10 mg dose on alternating days until the Sezary count was
<1000/mm3. With the exception of a single patient whose best
response was stable disease, 9 out of 10 patients treated in this man-
ner achieved a response, 3 of which were complete. For most patients,
the time to treatment failure exceeded 12 months. What is notable,
however, is that infectious complications were not observed in patients
treated with the lowest dose (i.e., 10 mg) of alemtuzumab. Similar
results, with no infectious complications, were recently reported in a
small cohort of patients treated with modified, low-dose, subcutaneous
alemtuzumab for six weeks.244 In addition to hematologic toxicity, con-
ventionally dosed alemtuzumab in advanced-stage MF/SS is associated
with a high incidence of infectious complications.242,243,245–248 Overall,
infectious complications have been observed in two-thirds of treated
patients, most of which are bacterial, including sepsis. Cytomegalovirus
(CMV) reactivation is the most common viral infection. In addition,
Pneumocystis jirovecii pneumonia and invasive fungal infections have
also been observed. Therefore, trimethoprim-sulphamethoxazole and
acyclovir should be routinely administered for PJP and HSV/VZV pro-
phylaxis, respectively, in patients receiving alemtuzumab. In addition,
CMV surveillance should be performed every 1–2 weeks by quantita-
tive PCR and suppressive therapy with ganciclovir or oral valganciclovir
initiated in response to viral reactivation. Low-dose, subcutaneous
alemtuzumab appears to be safe and efficacious in selected patients
with advanced-stage MF/SS provided with appropriate supportive
care. Monoclonal antibodies targeting additional T-cell specific anti-
gens, including CD2,249 CD4,250 CD25,251 and CCR4252–254 are being
explored and appear promising. Mogamulizumab (KW-0761) is a
humanized monoclonal antibody specific for the chemokine receptor
CCR4 that has been defucosylated and is consequently associated with
enhanced antibody-dependent cell-mediated cytotoxicity (ADCC). In a
phase I/2 study, mogamulizumab was well tolerated and was associ-
ated with an overall response rate of 37%. A similar response rate of
29% (2/7), all partial, was observed in a phase II Japanese study.254,255
In addition to ADCC-mediated clearance of malignant T cells, mogamu-
lizumab may inhibit Treg-mediate immune suppression,
256,257 and may
warrant further investigation with immunomodulatory therapies,
including immune checkpoint blockade.258 A randomized, phase III clin-
ical trial comparing mogamulizumab and vorinostat in relapsed/refrac-
tory CTCL is ongoing in the US (NCT01728805). While capable of
binding skin-resident T cells, monoclonal antibodies like mogamulizu-
mab and alemtuzumab may be most efficacious in MF/SS patients with
recirculating (and TMM or TCM-derived) clones.
21 Resimmune, a second-
generation immunotoxin in which the catalytic and translocation
domains of diphtheria toxin (DT390) have been fused to CD3-specific
single chain antibody fragments [bisFv(UCHT1)], is associated with a
response rate of 36% (16% complete), and is particularly active in
patients with limited-stage disease.259 Much like its predecessor, resim-
mune is associated with a vascular leak syndrome.132
3.3.7 | Brentuximab vedotin
Brentuximab vedotin (BV) is an antibody-drug conjugate in which an
anti-CD30 monoclonal antibody is linked with an anti-tubulin agent
(monomethyl auristatin E). Among 30 MF/SS patients that were evalu-
able for response in the phase II study reported by Kim et al., an overall
response rate of 70% was observed.260 A randomized, phase III clinical
trial (ALCANZA) comparing brentuximab vedotin with an investigator’s
choice (methotrexate or bexarotene) was recently reported in abstract
form and demonstrated a significantly improved PFS (>12 months vs.
3.5 months) for patients randomized to brentuximab vedotin.
3.3.8 | Checkpoint blockade
Durable remissions may be achieved with immunomodulatory thera-
pies, including extracorporeal photopheresis (ECP) and interferon-a.
While largely anecdotal, these observations suggest that host immu-
nity, when properly harnessed, can lead to durable responses in
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selected patients. These observations, coupled with high-level PD-L1
expression in a substantial minority of patients, provide a strong ration-
ale for checkpoint blockade (CPB) in CTCL.52,261 While few CTCL
patients have been included in early phase clinical trials, durable
responses have been observed, including two responding CTCL
patients who achieved responses that were ongoing at 241 and 501
weeks.262 Preliminary data from an ongoing phase II study with pem-
brolizumab in relapsed/refractory mycosis fungoides (MF) and Sezary
syndrome (SS) appears similarly promising, with an overall response
rate (ORR) of 33% in MF/SS, including in patients with advanced-stage
disease.261 These encouraging preliminary results, in conjunction with
the smorgasbord of currently available immunomodulatory agents,
including HDAC inhibitors, may lend themselves to future combinato-
rial strategies.261
3.3.9 | Systemic chemotherapy
Responses to conventional chemotherapeutic agents are rarely durable
in CTCL, being associated with a median time-to-next treatment that is
measured in months.148,149 Consequently, >90% of patients treated in
this manner will require additional therapy within the first year of ther-
apy. If used, conventional chemotherapeutic agents are reserved for
patients with advanced-stage MF/SS who have multiply relapsed dis-
eased and have few therapeutic options, including clinical trial partici-
pation, remaining or have extensive disease with visceral organ
involvement that requires rapid debulking. Multiple chemotherapeutic
agents, including single-agent and combination chemotherapy regi-
mens, while associated with high response rates in MF/SS,151,153,263
are infrequently durable,148,149 and frequently associated with signifi-
cant myelosuppression and infectious complications.148,264–266 There-
fore, with the exceptions of refractory disease or in the setting of
extensive or rapidly progressive disease where a rapid treatment
response may be necessary, the administration of sequential, single-
agent chemotherapy is preferred. Many oral and intravenous chemo-
therapeutic agents have been utilized in MF/SS.267–287 Unfortunately,
the duration of response with these agents is frequently measured in
months. Therefore, novel therapeutic agents, either alone or in combi-
nation, are needed.
Pralatrexate, a novel antifolate with a high affinity for the reduced
folate carrier (RFC-1) and novel mechanism of resistance when com-
pared with methotrexate,288–290 was associated with an overall
response rate of 29% in the PROPEL study. This study was comprised
largely of peripheral T-cell lymphoma patients, most of whom had
refractory disease.291 Notably, twelve patients with transformed MF
were included in the study.292 Many of these patients had received
more than 5 prior systemic therapies, including CHOP or CHOP-like
regimens. With only a single exception, these patients were refractory
to their most recent therapy. Responses, as assessed by the study inves-
tigators, were observed in 58% of patients with a median duration of
response and progression-free survival of 4–5 months. Results of a
dose-finding study were reported in a larger cohort of CTCL patients.293
In this study, the optimal dose was identified as 15 mg/m2, given
weekly 3 weeks out of 4, and was associated with an overall response
rate of 43%. In an effort to reduce the incidence of mucositis, folic acid
and vitamin B12 supplementation is routinely provided in these
patients.294 Additional therapeutic approaches, including proteasome
inhibition,295 immunomodulatory strategies,296 and more targeted
approaches warrant further investigation.72,297 As there is no standard
of care for patients with MF/SS requiring systemic chemotherapy and
the decision to initiate therapy is individualized, including consideration
of responses and complications related to prior therapies, participation
in a well-designed clinical trial is always worth consideration.
3.3.10 | High-dose chemotherapy and hematopoietic stem
cell transplantation
The available experience with high-dose chemotherapy and autologous
stem cell transplantation, largely confined to case series, suggests that
responses following treatment are frequently transient. In contrast, the
durable remissions observed following allogeneic transplantation may be
explained by the graft versus lymphoma immune response.298,299 A ret-
rospective analysis of 60 patients with advanced-stage MF/SS who
underwent allogeneic stem cell transplantation was recently reported.300
In this series, patients had received a median of 4 prior therapies prior to
undergoing either reduced-conditioning (73%) or myeloablative (27%)
conditioning prior to related (75%) or matched-unrelated donor (25%)
transplantation. Nonrelapse mortality at 1 year was 14% for patients
receiving reduced-intensity conditioning or HLA identical/related donor
stem cells and 38–40% for those undergoing myeloablative conditioning
or receiving match-unrelated donor grafts. Transplantation during an
early phase of disease (defined as first or second remission or relapse fol-
lowing 3 or fewer systemic therapies) was associated with lower relapse
rates (25% vs. 44% at 1 year) and a statistically insignificant increase in 3-
year overall survival (68% vs. 46%). Given the differences in nonrelapse
mortality, both reduced-intensity conditioning and use of matched-
related donors were associated with superior overall survival (63% at 3
years). Seventeen out of 26 patients who relapsed received donor-
lymphocyte infusions. Of these, 47% achieved a complete remission,
thus providing evidence for a graft-versus-lymphoma effect in MF/SS. In
contrast to the experience with B-cell non-Hodgkin lymphomas, chemo-
therapy sensitivity prior to transplantation or the extent of disease bur-
den did not influence overall survival. The estimated 3-year progression-
free and overall survival were 34% and 53%, respectively. Given the pos-
sibility of complete and durable remissions, allogeneic stem-cell trans-
plantation in conjunction with total skin electron beam therapy may be
considered in selected patients.209,301
4 | SUMMARY
Establishing a definitive diagnosis of CTCL, accurate disease staging
and risk-stratification, and the selection of appropriate therapy requires
a multidisciplinary approach. While high response rates may be
achieved with systemic chemotherapy, these responses are frequently
short-lived and associated with significant toxicities. As treatment of
advanced-stage MF/SS is largely palliative, a stage-based approach uti-
lizing sequential therapies in an escalated fashion is preferred. Partici-
pation in a well-designed clinical trial is encouraged, as the introduction
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of novel agents will continue to expand the therapeutic options avail-
able in the management of CTCL.
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